KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (Weighted Average): 2011-2025

Historic Shares Outstanding (Weighted Average) for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $56.1 million.

  • Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.76% to $56.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.1 million, marking a year-over-year increase of 1.76%. This contributed to the annual value of $55.2 million for FY2024, which is 1.07% up from last year.
  • Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $56.1 million in Q3 2025, which was up 0.15% from $56.0 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $56.1 million during Q3 2025, and registered a low of $52.9 million during Q1 2021.
  • Over the past 3 years, Supernus Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $55.0 million (recorded in 2024), while the average stood at $55.1 million.
  • Data for Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY grew of 2.25% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $53.2 million in 2021, then climbed by 1.65% to $54.1 million in 2022, then increased by 1.06% to $54.6 million in 2023, then rose by 1.07% to $55.2 million in 2024, then rose by 1.76% to $56.1 million in 2025.
  • Its last three reported values are $56.1 million in Q3 2025, $56.0 million for Q2 2025, and $55.8 million during Q1 2025.